Outcomes for Children with Brain Tumors
Outcomes for children with brain tumors vary dramatically by tumor type and molecular subtype, ranging from excellent (>90% long-term survival for WNT-activated medulloblastoma) to poor (<20% 5-year survival for diffuse high-grade gliomas), with survival being only one component—neurocognitive impairment, treatment-related toxicities, and quality of life deficits affect the majority of survivors regardless of cure.
Survival Outcomes by Tumor Type
High-Grade Gliomas
The prognosis for pediatric diffuse high-grade gliomas remains generally poor with 5-year survival rates of <20% despite multimodal therapy combining surgery, radiation, and systemic treatment 1. Survival depends critically on:
- Age at presentation (children <3 years have better outcomes with chemotherapy alone: 44% 5-year event-free survival vs 0% for children ≥72 months) 1
- Tumor location (pontine diffuse midline gliomas have particularly poor prognosis with limited treatment options after progression) 1
- Extent of resection (gross total resection improves outcomes)
- Molecular profile (BRAF V600E mutations, TRK fusions, and hypermutant tumors offer targeted therapy options)
For high-grade gliomas treated with radiation plus temozolomide and lomustine, 3-year event-free survival reaches only 22% and overall survival 28%, though this represents improvement over temozolomide alone 1.
Medulloblastoma
Approximately 75% of children with medulloblastoma achieve prolonged survival with current multimodality therapies 1. However, outcomes vary dramatically by molecular subtype:
- WNT-activated tumors: >90% long-term survival (best prognosis) 1
- SHH-activated, TP53-wild-type: Intermediate prognosis
- SHH-activated, TP53-mutant with MYCN amplification: Very poor outcome 1
- Group 4 tumors: 75-90% overall survival 1
- Group 3 tumors: 20-30% 5-year survival (worst prognosis) 1
Patients <3 years, those with metastatic disease, suboptimal resection, and certain molecular subtypes have worse prognosis 1.
Low-Grade Tumors
Children with low-grade tumors demonstrate 82% 20-year survival compared to 33% for high-grade tumors 2. Those treated with surgical resection alone without adjuvant therapy show excellent clinical outcomes, with two-thirds achieving full-time employment as adults 2.
Neurocognitive and Quality of Life Outcomes
Universal Impact
Neurological, cognitive, and neuropsychological deficits are the most disabling long-term effects of pediatric brain tumors, affecting multiple developmental domains and day-to-day functioning 3. These impairments occur regardless of survival status and represent a critical component of overall outcome assessment.
Specific Cognitive Deficits
Children demonstrate major deficits in:
- Narrative memory (impaired at baseline and persisting post-surgery) 4
- Visuo-spatial memory and processing (deficits in copy design tasks persist long-term) 4
- Visual-motor coordination (remains impaired post-surgery) 4
- IQ decline over time (median IQ drops from 100 at baseline to 93 at 18-24 months post-treatment) 4
Cognitive decline may worsen progressively over time rather than stabilize, necessitating ongoing monitoring 4.
Treatment-Specific Effects
- Proton radiotherapy produces better neurocognitive and academic outcomes than photon radiotherapy 5
- Early-stage radiotherapy affects cognitive abilities regardless of other treatment factors 5
- Delayed high-dose radiotherapy and marrow ablation chemotherapy produce worse long-term outcomes 5
- Intrathecal methotrexate and radiation are associated with particularly poor neurocognition 6
Psychosocial Outcomes
Survivors experience:
- Low self-esteem
- Depressive symptoms
- Increased suicidal ideation
- Subpar quality of life affecting academic endeavors and social interaction 5
Functional Outcomes in Long-Term Survivors
Among 20-year survivors of infantile brain tumors (diagnosed <3 years):
- 50 of 52 survivors (96%) achieved a Barthel Index of 100 (complete independence in activities of daily living) 2
- 32 of 52 (62%) achieved full-time employment 2
- 10 additional survivors (19%) achieved part-time employment 2
- 10 survivors (19%) had no working capacity 2
The functional level of long-term survivors is most affected by adjuvant therapy, particularly radiotherapy 2.
Critical Pitfalls and Monitoring Strategies
Pseudoprogression
Pseudoprogression may occur within 6-9 months after radiation therapy and can mimic true progression on MRI 1. This must be considered when evaluating imaging changes during this critical window to avoid premature treatment escalation.
Need for Baseline Assessment
Baseline and periodic neurocognitive evaluations should be performed to indicate targets for cognitive monitoring and early detect functional difficulties 4. Many children present with neuropsychological impairments at diagnosis, before any treatment 4.
Late Effects Requiring Long-Term Follow-Up
Survivors require monitoring by knowledgeable clinical staff for:
- Neoplastic disease recurrence
- Potential treatment side effects
- Progressive neurocognitive decline
- Neuroendocrine abnormalities
- Sensory deficits 2
Most pediatric patients with diffuse high-grade gliomas eventually develop tumor recurrence or progression, necessitating close surveillance with brain MRI every 2-3 months for the first year, then every 3-6 months indefinitely 1.